Phase 2 N=58 S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer
Fallopian Tube Cancer · Ovarian Cancer · Peritoneal Cavity Cancer
Primary: Overall Survival — 32 months
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=68 S9912 Combination Chemo in Stage III Ovarian Cancer,
Fallopian Tube Cancer · Ovarian Cancer · Peritoneal Cavity Cancer
Primary: Progression-free Survival — 25 months
Phase 3 N=4,312 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Primary Peritoneal Carcinoma · Stage III Ovarian Cancer · Stage IV Ovarian Cancer
Primary: Overall Survival — 0.35; 0.34; 0.39; 0.34 Proportion of participants
Phase 1 N=15 Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer
Fallopian Tube Cancer · Ovarian Cancer · Peritoneal Cavity Cancer
Primary: Maximum-tolerated Dose of Pemetrexed With a Day 2 i.p. Cisplatin (75 mg/m2) and Day 8 i.p. Paclitaxel (60 mg/m2) — 500 mg/m2
Phase 2 N=40 Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer
Platinum-sensitive Ovarian Cancer, Second-line, Third-line, or Fourth-line
Primary: Number of Participants With Drug-related Adverse Events (AEs) of Grade 3 or Higher — 20 Participants
Phase 3 N=1,301 A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Neoplasms
Primary: Progression-Free Survival (PFS) Assessed by Investigator as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) - Intent-to-Treat (ITT) Population…
Phase 2 N=28 Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma
Primary Peritoneal Carcinoma · Ovarian Carcinoma · Fallopian Tube Carcinoma
Primary: Percentage of Patients That Achieve Maximal Surgical Debulking — 10 Participants
Phase 2 N=42 Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Ovarian Cancer · Primary PERITONEUM · Fallopian Tube Cancer
Primary: Overall Objective Response — 10; 13; 11; 4 participants
Phase 3 N=1,560 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Fallopian Tube Clear Cell Adenocarcinoma · Fallopian Tube Endometrioid Adenocarcinoma · Fallopian Tube Mucinous Adenocarcinoma
Primary: Median Progression-free Survival — 24.9; 27.3; 26.0 months — p=0.341
Phase 2 N=275 Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer
Fallopian Tube Cancer · Metastatic Cancer · Ovarian Cancer
Primary: 9-month Progression Rate Post-randomization — 0.386; 0.347; 0.245 Porportion of participants — p=0.065
Phase 3 N=831 An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy
Genital Neoplasms, Female · Fallopian Tube Neoplasms · Ovarian Neoplasms
Primary: Progression Free Survival (PFS) — 20.0; 22.2 Months — p=0.199
Phase 2 N=62 Carboplatin Taxol Avastin in Ovarian Cancer (OVCA)
Ovarian Cancer
Primary: PFS — 29.8 Months
Phase 2 N=29 Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer
Ovarian Cancer
Primary: Progression Free Survival (PFS) of Combination Platinum Based Therapy With Anti-Programmed Death (PD)-1 Therapy Followed by Maintenance Anti-PD-1 Therapy in Patients…
Phase 2 N=33 First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Fallopian Tube Carcinoma · Fallopian Tube Clear Cell Adenocarcinoma · Fallopian Tube Endometrioid Adenocarcinoma
Primary: Number of Participants With Treatment Success — 23 Participants
Phase 3 N=1,873 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Fallopian Tube Clear Cell Adenocarcinoma · Fallopian Tube Endometrioid Adenocarcinoma · Fallopian Tube Mucinous Adenocarcinoma
Primary: Progression-free Survival — 11.0; 12.3; 15.3 months — p=0.448
Phase 2 N=111 Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Brenner Tumor · Malignant Ascites · Malignant Pleural Effusion
Primary: Progression Free Survival (PFS) — 15.4; 14.3 Months — p=0.31
Phase 2 N=32 Neoadjuvant Therapy for Ovarian Cancer
Epithelial Ovarian Cancer · Primary Peritoneal Cancer · Fallopian Tube Cancer
Primary: Number of Protocol Defined Adverse Events in Patients Receiving Neoadjuvant Carboplatin, Paclitaxel, and Bevacizumab — 7 protocol defined adverse events
Phase 1 N=13 Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
Fallopian Tube Cancer · Ovarian Cancer · Peritoneal Cavity Cancer
Primary: Number of Patients With Treatment-emergent Adverse Events — 12; 6; 6; 12 Participants
Phase 2 N=4 Phase II Study of Clinical Activity of Pegaspargase in Women With Relapsed or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer
Ovarian Neoplasms · Fallopian Tube Neoplasms · Primary Peritoneal Neoplasms
Primary: 6 Month Progression Free Survival — 0 Participants
Phase 2 N=3 Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Platinum-Resistant Fallopian Tube Carcinoma · Platinum-Resistant Ovarian Carcinoma · Platinum-Resistant Primary Peritoneal Carcinoma
Primary: Objective Response Rate (ORR) — 2; 0 Participants
Phase 2 N=1 Salvage Ovarian FANG™ Vaccine + Carboplatinum
Stage III Ovarian Cancer · Stage IV Ovarian Cancer
Primary: Time to Progression (TTP)
Phase 2 N=150 Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
Ovarian Cancer
Primary: Progression-free Survival (PFS) — 13.7; 8.4 months
Phase 2 N=90 Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer
Ovarian Clear Cell Cystadenocarcinoma · Stage III Ovarian Cancer · Stage IV Ovarian Cancer
Primary: Proportion of Patients Who Are Alive and Progression-free for at Least 12 Months After Study Entry in Patients With Newly Diagnosed Stage III or IV Clear Cell Ovarian…
Phase 2 N=51 Ixabepilone in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer That Has Not Responded to Previous Chemotherapy
Primary Peritoneal Cavity Cancer · Recurrent Ovarian Epithelial Cancer
Primary: Tumor Response — 14.3 percentage of participants
Phase 2 N=85 Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer
Ovarian Cancer
Primary: 2-year Progression-free Survival — 40; 40 percentage of participants
Phase 3 N=140 OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer
Ovarian Cancer
Primary: Efficacy Patient Level — 26.9 percentage of participants
Phase 1 N=9 Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian
Ovarian Cancer · Primary Peritoneal Cancer · Fallopian Tube Cancer
Primary: Tolerated Dose — 80 mg/m^2
Phase 2 N=5 Salvage Ovarian FANG™ Vaccine + Bevacizumab
Stage III Ovarian Cancer · Stage IV Ovarian Cancer
Primary: Time to Progression
Phase 2 N=18 Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer
Ovarian Neoplasms Malignant (Excl Germ Cell) · Peritoneal Carcinoma · Fallopian Tube Cancer
Primary: Number of Participants With Dose-Limiting Toxicity (DLT) — 0; 0; 0; 0 Participants
Phase 2 N=55 Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer
Ovarian Neoplasm · Fallopian Tube Cancer · Primary Peritoneal Cancer
Primary: Clinical Response Rate. — 0; 19; 21; 60 percentage of participants